The Weekly Litigation News Digest is now live. Subscribe now

A Liquid Formulation Of Long-Acting Insulin And Insulinotropic Peptide - EP2877201

The patent EP2877201 was granted to Hanmi Pharm on Jun 5, 2019. The application was originally filed on Jul 25, 2013 under application number EP13822545A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2877201

HANMI PHARM
Application Number
EP13822545A
Filing Date
Jul 25, 2013
Status
Granted And Under Opposition
May 3, 2019
Publication Date
Jun 5, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLEMar 5, 2020MARSHALLWITHDRAWN

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONKR100725315B
DESCRIPTIONKR101058290B
DESCRIPTIONKR20110134210
DESCRIPTIONUS5424286
INTERNATIONAL-SEARCH-REPORTKR20110111267
INTERNATIONAL-SEARCH-REPORTKR20120135123
INTERNATIONAL-SEARCH-REPORTWO2011058082
INTERNATIONAL-SEARCH-REPORTWO2011144673
SEARCHUS2009238838

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents